within Pharmacolibrary.Drugs.ATC.R;

model R05CB01_1
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.4999999999999995e-06,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00047,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0005899999999999999,
    k12             = 0.84,
    k21             = 0.84
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R05CB01_1</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Acetylcysteine (N-acetylcysteine, NAC) is a mucolytic agent used to break down mucus, particularly in the lungs. It is also used as an antidote for acetaminophen (paracetamol) overdose. Approved and widely used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in patients after intravenous administration of NAC for acetaminophen overdose (standard 21-hour protocol).</p><h4>References</h4><ol><li><p>Chiew, AL, et al., &amp; Buckley, NA (2018). Interventions for paracetamol (acetaminophen) overdose. <i>The Cochrane database of systematic reviews</i> 2(2) CD003328–None. DOI:<a href=\"https://doi.org/10.1002/14651858.CD003328.pub3\">10.1002/14651858.CD003328.pub3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29473717/\">https://pubmed.ncbi.nlm.nih.gov/29473717</a></p></li><li><p>Forrest, JA, et al., &amp; Prescott, LF (1982). Clinical pharmacokinetics of paracetamol. <i>Clinical pharmacokinetics</i> 7(2) 93–107. DOI:<a href=\"https://doi.org/10.2165/00003088-198207020-00001\">10.2165/00003088-198207020-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7039926/\">https://pubmed.ncbi.nlm.nih.gov/7039926</a></p></li><li><p>Orgel, E, et al., &amp; Freyer, DR (2023). Intravenous N-Acetylcysteine to Prevent Cisplatin-Induced Hearing Loss in Children: A Nonrandomized Controlled Phase I Trial. <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 29(13) 2410–2418. DOI:<a href=\"https://doi.org/10.1158/1078-0432.CCR-23-0252\">10.1158/1078-0432.CCR-23-0252</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37134194/\">https://pubmed.ncbi.nlm.nih.gov/37134194</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R05CB01_1;
